Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 13, 2021
Purpose: Disclosure of an investor presentation (Exhibit 99.1) pursuant to Regulation FD for meetings with institutional investors and analysts. The presentation replaces all prior investor presentations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to announce the availability of an investor presentation; it does not contain audited financial statements or specific financial data points.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The primary change noted is the replacement of all prior investor presentations with the new presentation dated September 2021.
Guidance, Outlook, and Risks
Management Commentary: The Company states that the information in the investor presentation may be amended or updated at any time through future filings or other means.
Forward-Looking Statements: The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks: The Company reserves the right to discontinue the availability of the presentation on its website at any time.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation dated September 2021) for specific financial data and strategic updates not included in this 8-K summary.
- Verify the current availability of the presentation on the Company's website (www.aquestive.com), noting the Company's right to remove it.
- Check for subsequent 8-K filings or 10-Q/10-K reports for updated financial metrics and any amendments to the information presented.